83 (95% CI: 0.46–1.52) for pooled FL-rFVIII and BDD-rFVIII; 0.42 (0.19–0.93) for pooled FL-rFVIII; and 2.61 (1.21–5.53) for pooled BDD-rFVIII (Fig. 1). Once again, however, the generalisability of the results of this meta-analysis is limited by the quality of the selleck inhibitor studies available for inclusion. The actual number of patients with inhibitors was small (35 in total) and the confidence interval for the pooled BDD-rFVIII result was particularly large. Such limitations introduce the possibility of type 1 error when interpreting the findings. Perhaps the main message to emerge from this meta-analysis is that the incidence of de novo inhibitors in PTPs receiving any rFVIII concentrate (either

full length or B-domain deleted) is about 1%, which is substantiated by the narrow confidence interval (0.46–1.52) and is similar to that reported in other analyses. However, whether a real difference exists between full-length and BDD-rFVIII continues to remain uncertain www.selleckchem.com/products/PLX-4720.html [12]. At present, clotting factor therapy is relatively inconvenient because prophylaxis is done on a large scale and tends to involve repeated intravenous infusions, generally 2–3 times weekly or even daily by patient choice. On the other hand, there is a genuine need to consider the various challenges to innovation of haemophilia treatment as patient satisfaction with the current range of products is already quite high.

On this note, clinical trial protocols prescribed by regulatory agencies are becoming increasingly demanding which presents a very real obstacle to the design and conduct of randomized, controlled trials – especially within the context of a rare disorder such as haemophilia B – and in light of the high costs associated with conducting clinical trials. The potential also exists for neo-antigenicity to emerge as a result of molecular manipulation

which often comes to light only once the product has passed through clinical trial stage and is used in the wider population. 上海皓元医药股份有限公司 The current range of FVIII products has an approximate plasma half-life of 10–12 h (longer for FIX) which underlies the need for repeated infusions. As such, it is not surprising that approaches to prolong its half-life have been leading attempts to improve factor replacement therapy for patients with haemophilia. The potential benefits of longer-acting factors include extended protection from bleeding, reduced infusion frequency, and the possibility of avoiding a central catheter for venous access and its attendant issues. The first approach attempted to prolong plasma half-life was to attach FVIII to a ‘sustained-release’ delivery vehicle (e.g. liposomes), but this proved unsuccessful and has since been abandoned. Current approaches under investigation involve hydrophilic polymer conjugation (e.g. PEGylation) and variant protein generation (e.g. fusion factors).

Recent advances in imaging have enhanced our understanding of the morphological adaptations of muscle in response to disease and altered use. Adaptation in muscle morphology has been linked to changes in muscle strength. To date, no studies have compared muscle morphology and strength in young children with haemophilia to that of typically developing children. This study Selleck RAD001 explored differences in muscle strength and morphology between typically developing and age and size-matched boys aged 6–12 years with haemophilia and a history of recurrent haemorrhage in the ankle joint. Maximum muscle strength of the knee flexors (KF), extensors (KE), ankle dorsi

(ADF) and plantar flexors (APF) was measured in 19 typically developing boys (Group 1) and 19 boys with haemophilia (Group 2). Ultrasound images of vastus lateralis (VL) and lateral gastrocnemius (LG) were recorded to determine muscle cross-sectional area (CSA), thickness, width, fascicle length and pennation angle. Muscle strength of the KE, ADF

and APF were significantly (P < 0.05) lower in Group 2 when compared with Group 1. Muscle CSA and width of VL were significantly smaller and pennation angles significantly larger in Group 2 (P < 0.05). Muscle CSA and thickness of LG were significantly (P < 0.05) smaller in Group 2. Linear regression showed that LG muscle CSA and thickness were significant (P < 0.01) predictors of APF muscle strength. Following ankle joint bleeding selleckchem in young boys with haemophilia, secondary adaptations

in muscle strength and morphology were observed, suggesting that muscle function is more impaired than current clinical evaluations imply. “
“Summary.  Factor V (FV) deficiency is a rare coagulation disorder, characterized by a bleeding phenotype varying from mild to severe. To date, 115 mutations have been described along the gene encoding for FV (F5) but only few of them have been functionally characterized. Aim of this study was the identification and the molecular characterization of genetic defects underlying severe FV deficiency in a 7-month-old 上海皓元医药股份有限公司 Turkish patient. Mutation detection was performed by sequencing the whole F5 coding region, exon–intron boundaries and about 300 bp of the promoter region. Functional analysis of the identified missense mutation was conducted by transient expression of wild-type and mutant FV recombinant molecules in COS-1 cells. Two novel mutations: a missense (Pro132Arg) and a 1-bp deletion (Ile1890TyrfsX19) were identified in the F5 gene. While the frameshift mutation is responsible for the introduction of a premature stop codon, likely triggering F5 mRNA to nonsense-mediated mRNA degradation, the demonstration of the pathogenic role of the Pro132Arg mutation required an experimental validation.

Recent advances in imaging have enhanced our understanding of the morphological adaptations of muscle in response to disease and altered use. Adaptation in muscle morphology has been linked to changes in muscle strength. To date, no studies have compared muscle morphology and strength in young children with haemophilia to that of typically developing children. This study AZD5363 datasheet explored differences in muscle strength and morphology between typically developing and age and size-matched boys aged 6–12 years with haemophilia and a history of recurrent haemorrhage in the ankle joint. Maximum muscle strength of the knee flexors (KF), extensors (KE), ankle dorsi

(ADF) and plantar flexors (APF) was measured in 19 typically developing boys (Group 1) and 19 boys with haemophilia (Group 2). Ultrasound images of vastus lateralis (VL) and lateral gastrocnemius (LG) were recorded to determine muscle cross-sectional area (CSA), thickness, width, fascicle length and pennation angle. Muscle strength of the KE, ADF

and APF were significantly (P < 0.05) lower in Group 2 when compared with Group 1. Muscle CSA and width of VL were significantly smaller and pennation angles significantly larger in Group 2 (P < 0.05). Muscle CSA and thickness of LG were significantly (P < 0.05) smaller in Group 2. Linear regression showed that LG muscle CSA and thickness were significant (P < 0.01) predictors of APF muscle strength. Following ankle joint bleeding Selleckchem ABT888 in young boys with haemophilia, secondary adaptations

in muscle strength and morphology were observed, suggesting that muscle function is more impaired than current clinical evaluations imply. “
“Summary.  Factor V (FV) deficiency is a rare coagulation disorder, characterized by a bleeding phenotype varying from mild to severe. To date, 115 mutations have been described along the gene encoding for FV (F5) but only few of them have been functionally characterized. Aim of this study was the identification and the molecular characterization of genetic defects underlying severe FV deficiency in a 7-month-old MCE公司 Turkish patient. Mutation detection was performed by sequencing the whole F5 coding region, exon–intron boundaries and about 300 bp of the promoter region. Functional analysis of the identified missense mutation was conducted by transient expression of wild-type and mutant FV recombinant molecules in COS-1 cells. Two novel mutations: a missense (Pro132Arg) and a 1-bp deletion (Ile1890TyrfsX19) were identified in the F5 gene. While the frameshift mutation is responsible for the introduction of a premature stop codon, likely triggering F5 mRNA to nonsense-mediated mRNA degradation, the demonstration of the pathogenic role of the Pro132Arg mutation required an experimental validation.

05). In multivariate analysis, independent predictors of HCV/AIH were ANA positivity, female sex, higher HCV RNA, ALT and globulin fraction. 11 liver

biopsies from HCV/AIH cases were compared to matched controls. There was no difference in the presence of plasma cells in portal and lobular areas, rosette formation, emperipolesis, bridging necrosis and perivenular necrosis. However, HCV/AIH cases had higher periportal HAI inflammatory scores (p=.008) despite similar ALT levels. Conclusion: ANA positivity is common in patients with HCV (38%). Among patients with chronic HCV infection, ANA positivity, female sex, higher baseline HCV RNA, ALT, globulin fraction and greater periportal inflammation are suggestive of co-existent HCV/AIH. Disclosures: The following people have nothing to disclose: Yun Ju Kim, Anthony Loria, Xiongce Zhao, David E. Kleiner, Marc G. Ghany “
“RNA interference (RNAi) is being evaluated Bafilomycin A1 order as an alternative therapeutic strategy for hepatitis C virus (HCV) infection. The use of Napabucasin viral vectors encoding short hairpin RNAs (shRNAs) has been the most common strategy employed to provide sustained expression of RNAi effectors.

However, overexpression and incomplete processing of shRNAs has led to saturation of the endogenous miRNA pathway, resulting in toxicity. The use of endogenous microRNAs (miRNAs) as scaffolds for short interfering (siRNAs) may avoid these problems, and miRNA clusters can be engineered to express multiple RNAi effectors, a feature that may prevent RNAi-resistant HCV mutant generation. We exploited the endogenous miRNA-17-92 cluster to generate 上海皓元医药股份有限公司 a polycistronic primary miRNA that is processed into five mature miRNAs that target different regions of the HCV genome. All five anti-HCV miRNAs were active, achieving

up to 97% inhibition of Renilla luciferase (RLuc) HCV reporter plasmids. Self-complementary recombinant adeno-associated virus (scAAV) vectors were chosen for therapeutic delivery of the miRNA cluster. Expression of the miRNAs from scAAV inhibited the replication of cell culture–propagated HCV (HCVcc) by 98%, and resulted in up to 93% gene silencing of RLuc-HCV reporter plasmids in mouse liver. No hepatocellular toxicity was observed at scAAV doses as high as 5 × 1011 vector genomes per mouse, a dose that is approximately five-fold higher than doses of scAAV-shRNA vectors that others have shown previously to be toxic in mouse liver. Conclusion: We have demonstrated that exogenous anti-HCV miRNAs induce gene silencing, and when expressed from scAAV vectors inhibit the replication of HCVcc without inducing toxicity. The combination of an AAV vector delivery system and exploitation of the endogenous RNAi pathway is a potentially viable alternative to current HCV treatment regimens. (HEPATOLOGY 2010.

2 mL of phosphate-buffered

saline [PBS]/mouse daily; antibody characterization is shown in Supporting Fig. 1). For treatment of mice with oleamide (Sigma-Aldrich, St. Louis, MO), the reagent was dissolved in dimethyl sulfoxide (15.6 mg/mL), diluted in olive oil, and injected intraperitoneally at 25 mg/200 μL/kg body weight once a day for 2 days before subsequent visualization. For treatment of mice with HGF or natural killer transcript 4 (NK4; a four-Kringle domain antagonist of HGF; gifts from Dr. Toshikazu Nakamura, Osaka University Medical School, Osaka, Japan), the proteins were injected intrasplenically (IS) at 2-4 μg/0.1 mL of PBS. Mice were buy Roxadustat visualized 1 hour later. Additional methods are described in the Supporting Information. Using TEM, we found STA-9090 that although the morphology of the hepatocytes from hepsin−/− mouse livers was similar to that of hepatocytes from WT mouse livers, the hepsin−/− hepatocytes were larger than those from WT mice, with a 22.6% increase in mean volume density (VV), as compared to WT (Fig. 1A). The size of hepsin−/− hepatocytes was also measured by in vivo live imaging of mice by IVM, which showed

an average 27.7% increase in the cross-sectional area of the hepatocytes of hepsin−/− mice, as compared to WT hepatocytes (Fig. 1B); these results ruled out possible interference from fixation and dehydration artifacts that might alter cell size or liver architecture. IVM also revealed that the hepsin−/− mice, but not WT mice, that received hydrodynamic delivery of hepsin DNA for transient hepsin expression (Supporting Fig. 2) had a reduced hepatocyte size (Fig. 1C). Moreover, antibody blockade by intravenous (IV) injection of mice with antihepsin altered hepatocyte size in the WT, but not the hepsin−/−, mice (Fig. 1D). Further analysis by flow cytometry also confirmed that hepsin−/− mouse hepatocytes were larger than those of WT mice, and that the hepsin−/− hepatocyte phenotype, but not the WT-hepatocyte phenotype, was reversed by reexpression of WT, but not mutant, hepsin medchemexpress (Supporting

Fig. 3). Together, these results suggest that hepsin expression level is associated with the regulation of hepatocyte size in vivo. Along with the change in hepatocyte size in hepsin−/− mice, TEM also revealed that liver sinusoids from hepsin−/− mice (5.63 ± 0.66 μm) were significantly narrower than those from WT mice (7.66 ± 1.26 μm; Fig. 2A). IVM also showed that the liver sinusoids of 4- and 8-week-old hepsin−/− mice were significantly narrower than those of age-matched WT mice (Fig. 2B). Graphic representation of the diameter distribution from 2,880 sinusoids measured in hepsin−/− livers showed a bell-shaped and left-shifted distribution, as compared to that from WT livers, suggesting that hepsin−/− liver sinusoids were generally narrower, but had the similar vessel densities to those of the WT livers (Supporting Fig. 4).

2 mL of phosphate-buffered

saline [PBS]/mouse daily; antibody characterization is shown in Supporting Fig. 1). For treatment of mice with oleamide (Sigma-Aldrich, St. Louis, MO), the reagent was dissolved in dimethyl sulfoxide (15.6 mg/mL), diluted in olive oil, and injected intraperitoneally at 25 mg/200 μL/kg body weight once a day for 2 days before subsequent visualization. For treatment of mice with HGF or natural killer transcript 4 (NK4; a four-Kringle domain antagonist of HGF; gifts from Dr. Toshikazu Nakamura, Osaka University Medical School, Osaka, Japan), the proteins were injected intrasplenically (IS) at 2-4 μg/0.1 mL of PBS. Mice were Rucaparib solubility dmso visualized 1 hour later. Additional methods are described in the Supporting Information. Using TEM, we found Small molecule library concentration that although the morphology of the hepatocytes from hepsin−/− mouse livers was similar to that of hepatocytes from WT mouse livers, the hepsin−/− hepatocytes were larger than those from WT mice, with a 22.6% increase in mean volume density (VV), as compared to WT (Fig. 1A). The size of hepsin−/− hepatocytes was also measured by in vivo live imaging of mice by IVM, which showed

an average 27.7% increase in the cross-sectional area of the hepatocytes of hepsin−/− mice, as compared to WT hepatocytes (Fig. 1B); these results ruled out possible interference from fixation and dehydration artifacts that might alter cell size or liver architecture. IVM also revealed that the hepsin−/− mice, but not WT mice, that received hydrodynamic delivery of hepsin DNA for transient hepsin expression (Supporting Fig. 2) had a reduced hepatocyte size (Fig. 1C). Moreover, antibody blockade by intravenous (IV) injection of mice with antihepsin altered hepatocyte size in the WT, but not the hepsin−/−, mice (Fig. 1D). Further analysis by flow cytometry also confirmed that hepsin−/− mouse hepatocytes were larger than those of WT mice, and that the hepsin−/− hepatocyte phenotype, but not the WT-hepatocyte phenotype, was reversed by reexpression of WT, but not mutant, hepsin MCE (Supporting

Fig. 3). Together, these results suggest that hepsin expression level is associated with the regulation of hepatocyte size in vivo. Along with the change in hepatocyte size in hepsin−/− mice, TEM also revealed that liver sinusoids from hepsin−/− mice (5.63 ± 0.66 μm) were significantly narrower than those from WT mice (7.66 ± 1.26 μm; Fig. 2A). IVM also showed that the liver sinusoids of 4- and 8-week-old hepsin−/− mice were significantly narrower than those of age-matched WT mice (Fig. 2B). Graphic representation of the diameter distribution from 2,880 sinusoids measured in hepsin−/− livers showed a bell-shaped and left-shifted distribution, as compared to that from WT livers, suggesting that hepsin−/− liver sinusoids were generally narrower, but had the similar vessel densities to those of the WT livers (Supporting Fig. 4).

Liver expression of transaminases might be associated with features of metabolic syndrome without necessarily involving liver injury. Disclosures: Carlos J. Pirola – Grant/Research Support: Merck Sharp and Dohme The following people have nothing to disclose: Silvia Sookoian, Gustavo O. Castaño, Tomas Fernández Gianotti, Romina Scian Background: Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in people; it is strongly associated with obesity.

Recently, irisin, a myokine secreted from exercised skeletal muscles, has been suggested as a promising target for managing NAFLD. Irisin activates thermogenic programs, and it is associated with glucose homeostasis SB525334 and liver fat content. However, less evidence is available on its associations with physical activity level and pathophysiological parameters in NAFLD subjects. Objective: We measured irisin levels to understand its secretory status in NAFLD subjects. We then correlated these levels with data on anthropometry, blood biochemistry, and ultrasonography to understand the association with pathophysiological parameters. Moreover, the effects of exercise training on the

irisin secretory status and its associated changes were studied in obese subjects with NAFLD. Methods Irisin levels were measured by ELISA in 37 healthy volunteers (age: 28 ± 10 years) and 274 NAFLD subjects (age: 52 ± 12 years). Anthropometric parameters, MAPK Inhibitor Library concentration body composition medchemexpress and blood biochemical indices, which included adipocytokine, glucose, and lipid and hepatic profiles, were determined. We divided the 274 NAFLD subjects into 4 groups according to physical activity levels and body adiposity (divided by BMI 30) for cross-sectional study: inactive & non obese (IN, n = 99); inactive & obese (IO, n = 51); active & non obese (AN, n = 85); and active & obese group (AO, n = 39). The 124 active subjects also completed an intervention study with a 12-week weight-loss program. Results Irisin levels were significantly lower in NAFLD subjects than in healthy volunteers (130 ± 41 vs. 335 ± 97; P<0.01).

Also, irisin levels were significantly higher in the active groups (AN; 197 ± 39 ng/ml, AO; 204 ± 34 ng/ml) than in the inactive groups (IN; 62 ± 34 ng/ml, IO; 55 ± 29 ng/ml). The hepatic steatosis levels (AN < IN < IO, AO) correlated with the irisin levels. In the weight-loss program, subjects with increased irisin levels (n = 72) had a greater reduction in fat mass, subcutaneous adipose area, γ-GTP, leptin, and TNFα levels compared to subjects without increased irisin levels (n = 42). Conclusion Irisin levels were significantly lower in NAFLD subjects, especially for the inactive group, and inversely correlated with the hepatic steatosis grade. The increased irisin levels seen after the weight-loss program were also associated with the attenuation of NAFLD pathological factors. Collectively, irisin may be a novel molecule important for NAFLD management.

Liver expression of transaminases might be associated with features of metabolic syndrome without necessarily involving liver injury. Disclosures: Carlos J. Pirola – Grant/Research Support: Merck Sharp and Dohme The following people have nothing to disclose: Silvia Sookoian, Gustavo O. Castaño, Tomas Fernández Gianotti, Romina Scian Background: Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in people; it is strongly associated with obesity.

Recently, irisin, a myokine secreted from exercised skeletal muscles, has been suggested as a promising target for managing NAFLD. Irisin activates thermogenic programs, and it is associated with glucose homeostasis Navitoclax concentration and liver fat content. However, less evidence is available on its associations with physical activity level and pathophysiological parameters in NAFLD subjects. Objective: We measured irisin levels to understand its secretory status in NAFLD subjects. We then correlated these levels with data on anthropometry, blood biochemistry, and ultrasonography to understand the association with pathophysiological parameters. Moreover, the effects of exercise training on the

irisin secretory status and its associated changes were studied in obese subjects with NAFLD. Methods Irisin levels were measured by ELISA in 37 healthy volunteers (age: 28 ± 10 years) and 274 NAFLD subjects (age: 52 ± 12 years). Anthropometric parameters, RG-7388 clinical trial body composition MCE公司 and blood biochemical indices, which included adipocytokine, glucose, and lipid and hepatic profiles, were determined. We divided the 274 NAFLD subjects into 4 groups according to physical activity levels and body adiposity (divided by BMI 30) for cross-sectional study: inactive & non obese (IN, n = 99); inactive & obese (IO, n = 51); active & non obese (AN, n = 85); and active & obese group (AO, n = 39). The 124 active subjects also completed an intervention study with a 12-week weight-loss program. Results Irisin levels were significantly lower in NAFLD subjects than in healthy volunteers (130 ± 41 vs. 335 ± 97; P<0.01).

Also, irisin levels were significantly higher in the active groups (AN; 197 ± 39 ng/ml, AO; 204 ± 34 ng/ml) than in the inactive groups (IN; 62 ± 34 ng/ml, IO; 55 ± 29 ng/ml). The hepatic steatosis levels (AN < IN < IO, AO) correlated with the irisin levels. In the weight-loss program, subjects with increased irisin levels (n = 72) had a greater reduction in fat mass, subcutaneous adipose area, γ-GTP, leptin, and TNFα levels compared to subjects without increased irisin levels (n = 42). Conclusion Irisin levels were significantly lower in NAFLD subjects, especially for the inactive group, and inversely correlated with the hepatic steatosis grade. The increased irisin levels seen after the weight-loss program were also associated with the attenuation of NAFLD pathological factors. Collectively, irisin may be a novel molecule important for NAFLD management.

The aim of this study was to evaluate the diagnostic yield of triple approach which cytology and histologic assessments with rapid on-site cytopathologic evaluation for one pass specimen during EUS-FNA in pancreatic solid masses and GDC-0449 lymph nodes (LNs). Methods: A prospective study was performed in 74 patients undergoing EUS-FNA to evaluate pancreatic solid masses or LNs. After one pass using 22 (transgastric pass) or 25 G (transduodenal pass) needle, specimen was divided three

segments. Air-dried smears with first segment were stained with Diff-Quick stain and immediately reviewed by cytopathologist to ascertain sample adequacy and onsite diagnosis. Second or third segment of each pass specimen prepared for Papanicolaou stain or histologic analysis with immunohistochemical (IHC) stain. Results: Of 74 patients, pancreatic masses and LNs were 58 (78.4%) and 16 (21.6%) patients. An onsite diagnosis was established in 50 (67.6%) patients with a mean of

1.60 needle passes. The diagnosis using cytology and histology with IHC stain were achieved in 65 (87.8%) and 62 (83.8%) patients, respectively. The sensitivity of cytology Fulvestrant ic50 and histology was 89% and 82%, respectively. The triple assessments showed 97% sensitivity and 100% specificity. Conclusion: On-site cytopathologic evaluation combined with cytologic and histologic analysis with IHC stain for one pass specimen can contribute to achieve the good results with EUS-FNA MCE公司 in pancreatic solid masses and LNs. Key Word(s): 1. EUS-FNA; 2. Pancreatic mass; 3. Lymph node; Presenting Author: YUNG KA CHIN Additional Authors: CHAI SOON NGUI, STEVENJOSEPH MESENAS, WAI CHOUNG ONG, CHRISTOPHER SAN CHOON KONG, BRIAN KIM POH GOH, ALEXANDER YAW FUI CHUNG, KIAT HON LIM, SU CHONG LOW, CHOON HUA THNG, DAMIEN

MENG YEW TAN Corresponding Author: YUNG KA CHIN, DAMIEN MENG YEW TAN Affiliations: Department of Gastroenterology and Hepatology; Department of hepatopancreatobiliary and transplantation surgery; Department of Pathology; Department of Diagnostic Radiology; Department of Oncologic Imaging Objective: Pancreatic cysts are being diagnosed with increasing frequency from the cross-sectional imaging. They have inherent malignant potential. Further characterisation with endoscopic ultrasound (EUS) with or without fine needle aspiration (FNA) has been shown to help in deciding when to resect the cyst. However the impact of EUS/FNA on affecting the decision making process varies between centres. This study is to evaluate the impact of EUS/FNA in the management of pancreatic cysts in our centre. Methods: Retrospective review of 111 EUS cases performed for pancreatic cysts between March 2008 and February 2013 by a single centre. Clinical characteristics, outcomes of patients, EUS/FNA, radiological and cytopathological diagnosis were reviewed. Results: We identified 111 patients with pancreatic cysts who had EUS/ FNA performed. Eighty-seven patients (78.

The aim of this study was to evaluate the diagnostic yield of triple approach which cytology and histologic assessments with rapid on-site cytopathologic evaluation for one pass specimen during EUS-FNA in pancreatic solid masses and Adriamycin lymph nodes (LNs). Methods: A prospective study was performed in 74 patients undergoing EUS-FNA to evaluate pancreatic solid masses or LNs. After one pass using 22 (transgastric pass) or 25 G (transduodenal pass) needle, specimen was divided three

segments. Air-dried smears with first segment were stained with Diff-Quick stain and immediately reviewed by cytopathologist to ascertain sample adequacy and onsite diagnosis. Second or third segment of each pass specimen prepared for Papanicolaou stain or histologic analysis with immunohistochemical (IHC) stain. Results: Of 74 patients, pancreatic masses and LNs were 58 (78.4%) and 16 (21.6%) patients. An onsite diagnosis was established in 50 (67.6%) patients with a mean of

1.60 needle passes. The diagnosis using cytology and histology with IHC stain were achieved in 65 (87.8%) and 62 (83.8%) patients, respectively. The sensitivity of cytology X-396 in vivo and histology was 89% and 82%, respectively. The triple assessments showed 97% sensitivity and 100% specificity. Conclusion: On-site cytopathologic evaluation combined with cytologic and histologic analysis with IHC stain for one pass specimen can contribute to achieve the good results with EUS-FNA 上海皓元医药股份有限公司 in pancreatic solid masses and LNs. Key Word(s): 1. EUS-FNA; 2. Pancreatic mass; 3. Lymph node; Presenting Author: YUNG KA CHIN Additional Authors: CHAI SOON NGUI, STEVENJOSEPH MESENAS, WAI CHOUNG ONG, CHRISTOPHER SAN CHOON KONG, BRIAN KIM POH GOH, ALEXANDER YAW FUI CHUNG, KIAT HON LIM, SU CHONG LOW, CHOON HUA THNG, DAMIEN

MENG YEW TAN Corresponding Author: YUNG KA CHIN, DAMIEN MENG YEW TAN Affiliations: Department of Gastroenterology and Hepatology; Department of hepatopancreatobiliary and transplantation surgery; Department of Pathology; Department of Diagnostic Radiology; Department of Oncologic Imaging Objective: Pancreatic cysts are being diagnosed with increasing frequency from the cross-sectional imaging. They have inherent malignant potential. Further characterisation with endoscopic ultrasound (EUS) with or without fine needle aspiration (FNA) has been shown to help in deciding when to resect the cyst. However the impact of EUS/FNA on affecting the decision making process varies between centres. This study is to evaluate the impact of EUS/FNA in the management of pancreatic cysts in our centre. Methods: Retrospective review of 111 EUS cases performed for pancreatic cysts between March 2008 and February 2013 by a single centre. Clinical characteristics, outcomes of patients, EUS/FNA, radiological and cytopathological diagnosis were reviewed. Results: We identified 111 patients with pancreatic cysts who had EUS/ FNA performed. Eighty-seven patients (78.